Search Results - "Paweletz, Cloud"

False positive plasma genotyping due to clonal hematopoiesis by Hu, Yuebi, Ulrich, Bryan, Supplee, Julianna, Kuang, Yanan, Lizotte, Patrick H, Feeney, Nora, Guibert, Nicolas, Awad, Mark M, Wong, Kwok-Kin, Janne, Pasi A, Paweletz, Cloud Peter, Oxnard, Geoffrey R

“…Plasma cell-free DNA (cfDNA) genotyping is increasingly used in cancer care, but assay accuracy is debated. Because most cfDNA is derived from peripheral blood…”
Get full text

Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies by Odegaard, Justin I, Vincent, John J, Mortimer, Stefanie, Vowles, James V, Ulrich, Bryan C, Banks, Kimberly C, Fairclough, Stephen R, Zill, Oliver A, Sikora, Marcin, Mokhtari, Reza, Abdueva, Diana, Nagy, Rebecca J, Lee, Christine E, Kiedrowski, Lesli A, Paweletz, Cloud P, Eltoukhy, Helmy, Lanman, Richard B, Chudova, Darya I, Talasaz, AmirAli

“…To analytically and clinically validate a circulating cell-free tumor DNA sequencing test for comprehensive tumor genotyping and demonstrate its clinical…”
Get full text

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M by Thress, Kenneth S, Paweletz, Cloud P, Felip, Enriqueta, Cho, Byoung Chul, Stetson, Daniel, Dougherty, Brian, Lai, Zhongwu, Markovets, Aleksandra, Vivancos, Ana, Kuang, Yanan, Ercan, Dalia, Matthews, Sarah E, Cantarini, Mireille, Barrett, J Carl, Jänne, Pasi A, Oxnard, Geoffrey R

“…A mutation conferring resistance to novel irreversible EGFR inhibitors is identified in cell-free plasma DNA from lung cancer patients. Here we studied…”
Get full text

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA by OXNARD, Geoffrey R, PAWELETZ, Cloud P, JÄNNE, Pasi A, YANAN KUANG, MACH, Stacy L, O'CONNELL, Allison, MESSINEO, Melissa M, LUKE, Jason J, BUTANEY, Mohit, KIRSCHMEIER, Paul, JACKMAN, David M

“…Tumor genotyping using cell-free plasma DNA (cfDNA) has the potential to allow noninvasive assessment of tumor biology, yet many existing assays are cumbersome…”
Get full text

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer by Oxnard, Geoffrey R, Thress, Kenneth S, Alden, Ryan S, Lawrance, Rachael, Paweletz, Cloud P, Cantarini, Mireille, Yang, James Chih-Hsin, Barrett, J Carl, Jänne, Pasi A

“…Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated potent activity against TKI resistance mediated by…”
Get full text

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C by Yaeger, Rona, Weiss, Jared, Pelster, Meredith S., Spira, Alexander I., Barve, Minal, Ou, Sai-Hong I., Leal, Ticiana A., Bekaii-Saab, Tanios S., Paweletz, Cloud P., Heavey, Grace A., Christensen, James G., Velastegui, Karen, Kheoh, Thian, Der-Torossian, Hirak, Klempner, Samuel J.

“…In heavily pretreated patients with mutant KRAS G12C colorectal cancer, adagrasib induced a response in 19% as single agent and in 46% in combination with…”
Get full text

Atypical Droplet Digital Polymerase Chain Reaction Patterns That Indicate Uncommon but Clinically Actionable EGFR Mutations in Lung Cancer by Lechner, Adam, Rai, Anooja, Rojas-Rudilla, Vanesa, Kuang, Yanan, Paweletz, Cloud P, Sholl, Lynette M, Dong, Fei

“…Droplet digital polymerase chain reaction (ddPCR) is a sensitive method to detect common pathogenic EGFR mutations in non-small cell lung cancer. Although…”
Get full text

Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients by Hu, Yuebi, Alden, Ryan S, Odegaard, Justin I, Fairclough, Stephen R, Chen, Ruthia, Heng, Jennifer, Feeney, Nora, Nagy, Rebecca J, Shah, Jayshree, Ulrich, Bryan, Gutierrez, Martin, Lanman, Richard B, Garber, Judy E, Paweletz, Cloud P, Oxnard, Geoffrey R

“…Plasma cell-free DNA (cfDNA) analysis is increasingly used clinically for cancer genotyping, but may lead to incidental identification of germline-risk…”
Get full text

Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer by Kitajima, Shunsuke, Ivanova, Elena, Guo, Sujuan, Yoshida, Ryohei, Campisi, Marco, Sundararaman, Shriram K, Tange, Shoichiro, Mitsuishi, Yoichiro, Thai, Tran C, Masuda, Sayuri, Piel, Brandon P, Sholl, Lynette M, Kirschmeier, Paul T, Paweletz, Cloud P, Watanabe, Hideo, Yajima, Mamiko, Barbie, David A

“…-driven lung cancers frequently inactivate and/or , defining tumor subclasses with emerging clinical relevance. Specifically, - (KL)-mutant lung cancers are…”
Get more information

3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade by Aref, Amir R, Campisi, Marco, Ivanova, Elena, Portell, Andrew, Larios, Dalia, Piel, Brandon P, Mathur, Natasha, Zhou, Chensheng, Coakley, Raven Vlahos, Bartels, Alan, Bowden, Michaela, Herbert, Zach, Hill, Sarah, Gilhooley, Sean, Carter, Jacob, Cañadas, Israel, Thai, Tran C, Kitajima, Shunsuke, Chiono, Valeria, Paweletz, Cloud P, Barbie, David A, Kamm, Roger D, Jenkins, Russell W

“…Microfluidic culture has the potential to revolutionize cancer diagnosis and therapy. Indeed, several microdevices are being developed specifically for…”
Get more information

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients by Paweletz, Cloud P, Sacher, Adrian G, Raymond, Chris K, Alden, Ryan S, O'Connell, Allison, Mach, Stacy L, Kuang, Yanan, Gandhi, Leena, Kirschmeier, Paul, English, Jessie M, Lim, Lee P, Jänne, Pasi A, Oxnard, Geoffrey R

“…Tumor genotyping is a powerful tool for guiding non-small cell lung cancer (NSCLC) care; however, comprehensive tumor genotyping can be logistically…”
Get full text

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma by Sade-Feldman, Moshe, Yizhak, Keren, Bjorgaard, Stacey L., Ray, John P., de Boer, Carl G., Jenkins, Russell W., Lieb, David J., Chen, Jonathan H., Frederick, Dennie T., Barzily-Rokni, Michal, Freeman, Samuel S., Reuben, Alexandre, Hoover, Paul J., Villani, Alexandra-Chloé, Ivanova, Elena, Portell, Andrew, Lizotte, Patrick H., Aref, Amir R., Eliane, Jean-Pierre, Hammond, Marc R., Vitzthum, Hans, Blackmon, Shauna M., Li, Bo, Gopalakrishnan, Vancheswaran, Reddy, Sangeetha M., Cooper, Zachary A., Paweletz, Cloud P., Barbie, David A., Stemmer-Rachamimov, Anat, Flaherty, Keith T., Wargo, Jennifer A., Boland, Genevieve M., Sullivan, Ryan J., Getz, Gad, Hacohen, Nir

“…Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of…”
Get full text

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib by Oxnard, Geoffrey R, Hu, Yuebi, Mileham, Kathryn F, Husain, Hatim, Costa, Daniel B, Tracy, Philip, Feeney, Nora, Sholl, Lynette M, Dahlberg, Suzanne E, Redig, Amanda J, Kwiatkowski, David J, Rabin, Michael S, Paweletz, Cloud P, Thress, Kenneth S, Jänne, Pasi A

“…Osimertinib mesylate is used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by the EGFR…”
Get more information

Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade by Rashidian, Mohammad, LaFleur, Martin W., Verschoor, Vincent L., Dongre, Anushka, Zhang, Yun, Nguyen, Thao H., Kolifrath, Stephen, Aref, Amir R., Lau, Christie J., Paweletz, Cloud P., Bu, Xia, Freeman, Gordon J., Barrasaf, M. Inmaculad, Weinberg, Robert A., Sharpe, Arlene H., Ploegh, Hidde L.

“…Immunotherapy using checkpoint-blocking antibodies against PD-1 has produced impressive results in a wide range of cancers. However, the response remains…”
Get full text

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC by Recondo, Gonzalo, Bahcall, Magda, Spurr, Liam F, Che, Jianwei, Ricciuti, Biagio, Leonardi, Giulia C, Lo, Ying-Chun, Li, Yvonne Y, Lamberti, Giuseppe, Nguyen, Tom, Milan, Marina S D, Venkatraman, Deepti, Umeton, Renato, Paweletz, Cloud P, Albayrak, Adem, Cherniack, Andrew D, Price, Kristin S, Fairclough, Stephen R, Nishino, Mizuki, Sholl, Lynette M, Oxnard, Geoffrey R, Jänne, Pasi A, Awad, Mark M

“…Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKI) are poorly understood. We aimed to characterize the genomic mechanisms of…”
Get full text

Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA by Supplee, Julianna G., Milan, Marina S.D., Lim, Lee P., Potts, Kristy T., Sholl, Lynette M., Oxnard, Geoffrey R., Paweletz, Cloud P.

“…•Next-generation sequencing (NGS) of cell-free DNA could expand access to precision medicine.•Technical differences between plasma NGS assays are poorly…”
Get full text

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics by Liu, Joyce F, Palakurthi, Sangeetha, Zeng, Qing, Zhou, Shan, Ivanova, Elena, Huang, Wei, Zervantonakis, Ioannis K, Selfors, Laura M, Shen, Yiping, Pritchard, Colin C, Zheng, Mei, Adleff, Vilmos, Papp, Eniko, Piao, Huiying, Novak, Marian, Fotheringham, Susan, Wulf, Gerburg M, English, Jessie, Kirschmeier, Paul T, Velculescu, Victor E, Paweletz, Cloud, Mills, Gordon B, Livingston, David M, Brugge, Joan S, Matulonis, Ursula A, Drapkin, Ronny

“…Ovarian cancer is the leading cause of death from gynecologic malignancy in the United States, with high rates of recurrence and eventual resistance to…”
Get full text

Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR by Williamson, Drew F K, Marris, Sean R N, Rojas-Rudilla, Vanesa, Bruce, Jacqueline L, Paweletz, Cloud P, Oxnard, Geoffrey R, Sholl, Lynette M, Dong, Fei

“…Activating mutations in EGFR predict benefit from tyrosine kinase inhibitor therapy for patients with advanced non-small cell lung cancer. Directing patients…”
Get full text

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer by Ge, Jennifer Y., Shu, Shaokun, Kwon, Mijung, Jovanović, Bojana, Murphy, Katherine, Gulvady, Anushree, Fassl, Anne, Trinh, Anne, Kuang, Yanan, Heavey, Grace A., Luoma, Adrienne, Paweletz, Cloud, Thorner, Aaron R., Wucherpfennig, Kai W., Qi, Jun, Brown, Myles, Sicinski, Piotr, McDonald, Thomas O., Pellman, David, Michor, Franziska, Polyak, Kornelia

“…BET inhibitors are promising therapeutic agents for the treatment of triple-negative breast cancer (TNBC), but the rapid emergence of resistance necessitates…”
Get full text

Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia by Bhatt, Shruti, Pioso, Marissa S., Olesinski, Elyse Anne, Yilma, Binyam, Ryan, Jeremy A., Mashaka, Thelma, Leutz, Buon, Adamia, Sophia, Zhu, Haoling, Kuang, Yanan, Mogili, Abhishek, Louissaint, Abner, Bohl, Stephan R., Kim, Annette S., Mehta, Anita K., Sanghavi, Sneha, Wang, Youzhen, Morris, Erick, Halilovic, Ensar, Paweletz, Cloud P., Weinstock, David M., Garcia, Jacqueline S., Letai, Anthony

“…Acquired resistance to BH3 mimetic antagonists of BCL-2 and MCL-1 is an important clinical problem. Using acute myelogenous leukemia (AML) patient-derived…”
Get full text